Figure S1. Pracinostat reactivates acetylation of non-histone protein tubulin at higher doses. Figure S2. Alteration in malignant behavior of cancer cell lines in vitro with Pracinostat treatment. Figure S3. ATF3 regulates the transcriptional activation of RB1. Figure S4. Pracinostat treatment inhibits in vivo tumor growth. Figure S5. Pracinostat treatment inhibits the production of proangiogenic factor VEGF- A in vitro. Figure S6. ATF3 reactivation is crucial in determining the sensitivity of the HDACi treatment in bladder cancer. Figure S7. The level of expression of HDAC enzymes may dictate the degree of sensitivity in different cell lines in vitro. Supplementary Methods: Generation of stable knockdown cells; Quantitative RT-PCR.